Lithium : interactions médicamenteuses

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

Table 5: Amiodarone Drug Interactions Concomitant Drug Class/Name Examples Clinical Comment QT Prolonging Drugs class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents Increased risk of Torsade de Pointes. (notice Amiodarone, Interactions médicamenteuses)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (notice Amphétamine, Mises en garde et précautions)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (notice Amphétamine et dexamfétamine, Mises en garde et précautions)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (notice Belladone et opium, Interactions médicamenteuses)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (notice Buprénorphine, Interactions médicamenteuses)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (notice Buprénorphine et naloxone, Interactions médicamenteuses)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (notice Butalbital, aspirine, caféine et codéine, Interactions médicamenteuses)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (notice Butalbital, paracétamol, caféine et codéine, Interactions médicamenteuses)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (notice Butorphanol, Précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (notice Codéine, Interactions médicamenteuses)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans,… (notice Dexamfétamine, Mises en garde)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (notice Fentanyl, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

Avoid concomitant use with lithium. (notice Furosémide, Interactions médicamenteuses)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (notice Hydrocodone, Interactions médicamenteuses)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (notice Hydrocodone et chlorphénamine, Interactions médicamenteuses)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (notice Hydrocodone et homatropine, Interactions médicamenteuses)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (notice Hydrocodone et ibuprofène, Précautions)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (notice Hydrocodone et paracétamol, Précautions)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (notice Hydromorphone, Interactions médicamenteuses)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (notice Lévorphanol, Précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (notice Lisdexamfétamine, Mises en garde et précautions)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (notice Métaxalone, Interactions médicamenteuses)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (notice Méthadone, Mises en garde et précautions)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (notice Méthamphétamine, Mises en garde et précautions)

L'association du millepertuis avec des antidépresseurs et d'autres médicaments sérotoninergiques augmente le risque de syndrome sérotoninergique. (NCCIH, St. John's Wort)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (notice Morphine, Interactions médicamenteuses)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

For specific information about the contraindications of lithium or valproate, refer to the Contraindications section of the package inserts for these other products. (notice Olanzapine, Contre-indications)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (notice Olicéridine, Interactions médicamenteuses)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (notice Oxycodone, Interactions médicamenteuses)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (notice Oxymorphone, Interactions médicamenteuses)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (notice Paracétamol et codéine, Précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (notice Pentazocine et naloxone, Précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (notice Prométhazine et codéine, Interactions médicamenteuses)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (notice Rémifentanil, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (notice Ziprasidone, Mises en garde et précautions)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (notice Lithium, Mises en garde et précautions)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Amiloride may be considered as a therapeutic agent for lithium-induced nephrogenic diabetes insipidus. (notice Lithium, Mises en garde et précautions)

Lithium Theophylline increases renal lithium clearance. (notice Aminophylline, Interactions médicamenteuses)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (notice Lithium, Interactions médicamenteuses)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (notice Lithium, Interactions médicamenteuses)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (notice Lithium, Interactions médicamenteuses)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (notice Lithium, Interactions médicamenteuses)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (notice Lithium, Interactions médicamenteuses)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, tramadol, tryptophan, buspirone, and St. (notice Lithium, Mises en garde et précautions)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (notice Lithium, Interactions médicamenteuses)

Lithium: Increases in serum lithium concentrations and lithium toxicity. (notice Azilsartan, Interactions médicamenteuses)

Lithium: Symptoms of lithium toxicity ( 7.6 ) (notice Bénazépril, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor Clinical Impact: Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, tramadol, tryptophan, buspirone, and St. (notice Lithium, Mises en garde et précautions)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Concomitant use of calcitonin salmon and lithium may lead to a reduction in plasma lithium concentrations due to increased urinary clearance of lithium. (notice Calcitonine de saumon, Interactions médicamenteuses)

Les compléments de calcium peuvent réduire l'absorption de ces médicaments ; prenez-les à plusieurs heures d'intervalle. (NIH Office of Dietary Supplements, Calcium)

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor Clinical Impact: Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations. (notice Lithium, Interactions médicamenteuses)

Lithium: Increases in serum lithium concentrations and toxicity ( 7 ). (notice Candésartan, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. (notice Captopril, Interactions médicamenteuses)

Methyldopa, Phenytoin and Carbamazepine Clinical Impact: Concomitant use may increase risk of adverse reactions of these drugs. (notice Lithium, Interactions médicamenteuses)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (notice Chlorure de calcium, Interactions médicamenteuses)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (notice Lithium, Interactions médicamenteuses)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor Clinical Impact: Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations. (notice Lithium, Interactions médicamenteuses)

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor Clinical Impact: Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (notice Lithium, Interactions médicamenteuses)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (notice Dronabinol, Mises en garde et précautions)

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor Clinical Impact: Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations. (notice Lithium, Interactions médicamenteuses)

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor Clinical Impact: Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations. (notice Lithium, Interactions médicamenteuses)

Monitor serum lithium levels frequently ( 7.4 ). (notice Énalapril, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Lithium Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. (notice Énalaprilate, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. (notice Fosinopril, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of Insulin Aspart Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. (notice Insuline asparte, Interactions médicamenteuses)

Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. (notice Insuline dégludec, Interactions médicamenteuses)

Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. (notice Insuline détémir, Interactions médicamenteuses)

Drugs that May Increase or Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. (notice Insuline glargine, Interactions médicamenteuses)

Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. (notice Insuline lispro, Interactions médicamenteuses)

Alcohol, Beta-blockers, Clonidine, and Lithium Salts Prevention or Management Monitor blood glucose more frequently and modify AFREZZA dosage, as clinically indicated, when used concomitantly with these drugs. (notice Insuline rapide (humaine), Interactions médicamenteuses)

Drug Interactions: Concurrent use with lithium or antithyroid drugs may potentiate the hypothyroid and goitrogenic effects of these medications. (notice Iodure de potassium, Interactions médicamenteuses)

Lithium: Risk of lithium toxicity. (notice Irbésartan, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (notice Lithium, Mises en garde et précautions)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (notice Lithium, Mises en garde et précautions)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (notice Lithium, Mises en garde et précautions)

Lithium: Symptoms of lithium toxicity ( 7.5 ) (notice Lisinopril, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Lithium: Risk of lithium toxicity. (notice Losartan, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Methyldopa, Phenytoin and Carbamazepine Clinical Impact: Concomitant use may increase risk of adverse reactions of these drugs. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. (notice Moexipril, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (notice Nalbuphine, Interactions médicamenteuses)

The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, tramadol, tryptophan, buspirone, and St. (notice Lithium, Mises en garde et précautions)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (notice Lithium, Interactions médicamenteuses)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (notice Lithium, Interactions médicamenteuses)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (notice Lithium, Interactions médicamenteuses)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (notice Lithium, Interactions médicamenteuses)

Lithium: Increases in serum lithium concentrations and lithium toxicity ( 7.4 ). (notice Olmésartan, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Lithium: Increase serum lithium levels, symptoms of lithium toxicity. (notice Périndopril, Interactions médicamenteuses)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

Methyldopa, Phenytoin and Carbamazepine Clinical Impact: Concomitant use may increase risk of adverse reactions of these drugs. (notice Lithium, Interactions médicamenteuses)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Decreased absorption of lithium and thyroxine have also been reported with co-administration of Sodium Polystyrene Sulfonate Powder, for Suspension. (notice Polystyrène sulfonate de sodium, Interactions médicamenteuses)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (notice Lithium, Mises en garde et précautions)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. (notice Quinapril, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Lithium: Use with caution (7.4). (notice Ramipril, Interactions médicamenteuses)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (notice Lithium, Interactions médicamenteuses)

Lithium: Increased risk of lithium toxicity. (notice Sacubitril et valsartan, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (notice Lithium, Interactions médicamenteuses)

Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists including telmisartan. (notice Telmisartan, Interactions médicamenteuses)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (notice Lithium, Mises en garde et précautions)

May lower theophylline seizure threshold Lithium Theophylline increases renal lithium clearance. (notice Théophylline, Interactions médicamenteuses)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (notice Lithium, Mises en garde et précautions)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

Lithium: Monitor serum lithium concentrations ( 7.1 ) (notice Tinidazole, Interactions médicamenteuses)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Monitor lithium levels if lithium is used with high-dose topiramate extended-release ( 7.7 ) (notice Topiramate, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (notice Lithium, Interactions médicamenteuses)

Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. (notice Trandolapril, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (notice Lithium, Mises en garde et précautions)

Lithium: Increases in serum lithium level and lithium toxicity ( 7.4 ) (notice Valsartan, Interactions médicamenteuses)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (notice Lithium, Interactions médicamenteuses)

Drugs Suspected of Causing Diabetes Insipidus Use with drugs suspected of causing diabetes insipidus (e.g., demeclocycline, lithium, foscarnet, clozapine) may decrease the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (notice Vasopressine, Interactions médicamenteuses)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (notice Lithium, Interactions médicamenteuses)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (notice Lithium, Interactions médicamenteuses)

The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, tramadol, tryptophan, buspirone, and St. (notice Lithium, Mises en garde et précautions)

Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents Clinical Impact: Concomitant use can lower serum lithium concentrations by increasing urinary lithium excretion. (notice Lithium, Interactions médicamenteuses)

Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents Clinical Impact: Concomitant use can lower serum lithium concentrations by increasing urinary lithium excretion. (notice Lithium, Interactions médicamenteuses)

Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents Clinical Impact: Concomitant use can lower serum lithium concentrations by increasing urinary lithium excretion. (notice Lithium, Interactions médicamenteuses)

Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents Clinical Impact: Concomitant use can lower serum lithium concentrations by increasing urinary lithium excretion. (notice Lithium, Interactions médicamenteuses)

John’s Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Drug Interactions ( 7.1 )]. (notice Lithium, Mises en garde et précautions)

Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome [see Adverse Reaction ( 6.2)]. (notice Oxycodone et paracétamol, Interactions médicamenteuses)

Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents Clinical Impact: Concomitant use can lower serum lithium concentrations by increasing urinary lithium excretion. (notice Lithium, Interactions médicamenteuses)

The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (notice Phentermine, Mises en garde et précautions)

Lithium Co-administration of valproate (500 mg BID) and lithium carbonate (300 mg TID) to normal male volunteers (n = 16) had no effect on the steady-state kinetics of lithium. (notice Acide valproïque, Interactions médicamenteuses)